Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06925269 · ClinicalTrials.gov registry record
DMD Voice: Qualitative Interviews With Patients and Caregivers
A clinical trial of Duchenne Muscular Dystrophy (DMD), sponsored by Red Nucleus Enterprise Solutions.
- Recruiting
- Registry status
- 68
- Enrollment target
- 1
- Study location
NCT06925269 is a study of Duchenne Muscular Dystrophy (DMD) that is actively recruiting participants, run by Red Nucleus Enterprise Solutions. The registered enrollment target is 68 participants, below the 81-participant average among 3 other Duchenne Muscular Dystrophy (DMD) trials with a reported enrollment target (16% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06925269, a study of Duchenne Muscular Dystrophy (DMD), is actively recruiting participants, sponsored by Red Nucleus Enterprise Solutions.
- RECRUITING
- Registry status
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand DMD functional losses or abilities and their association with independence and quality of life from the perspective of individuals with DMD and/or and their caregivers. This is a qualitative interview study in which individuals with DMD and/or their caregivers will be asked to participate in a semi-structured, approximately 60- minute interview. Interviews will focus on functional abilities and independence. Caregivers and boys with DMD will be interviewed. This study includes no treatment nor intervention; however, some participants are being treated by a drug that is approved in the U.S. and the U.K. and under investigation in other geographies.
Conditions Studied
Study Locations (1)
Pennsylvania
- Red Nucleus - Yardley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2025-03-31 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06925269
The ClinicalTrials.gov registry entry for NCT06925269 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 81-participant average among 3 other Duchenne Muscular Dystrophy (DMD) trials with a reported enrollment target (16% lower). The listed sponsor is Red Nucleus Enterprise Solutions, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Duchenne Muscular Dystrophy (DMD) appearing as the primary indexed condition, and to 0 interventions.
NCT06925269 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06925269 about?
NCT06925269 is a clinical study titled "DMD Voice: Qualitative Interviews With Patients and Caregivers". The purpose of this study is to understand DMD functional losses or abilities and their association with independence and quality of life from the perspective of individuals with DMD and/or and their caregivers. This is a qualitative interview study in which individuals with DMD and/or their caregi...
What is the current status of trial NCT06925269?
This trial is currently recruiting. The enrollment target is 68 participants. The study started on 2025-03-31. Estimated completion is 2026-12.
What conditions does trial NCT06925269 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy (DMD).
Who is sponsoring clinical trial NCT06925269?
This trial is sponsored by Red Nucleus Enterprise Solutions, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06925269 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy (DMD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders
RECRUITING
-
Urinary Titin Biomarker in DMD
RECRUITING · NA
-
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.